In several cancers, including colon cancer (14), lung adenocarcinoma (15), liver cancer (16), skin malignant tumors (17), and pancreatic cancer (18), IL-17A also affects the therapeutic efficacy and tumor prognosis (19). Here, IL17A is linked to neoplasm.